Skip Navigation

Journal of Tropical Pediatrics 1994 40(5):291-293; doi:10.1093/tropej/40.5.291
© 1994 by Oxford University Press
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Sakatoku, H.
Right arrow Articles by Afari, E. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sakatoku, H.
Right arrow Articles by Afari, E. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

research-article

Antibody Response to Measles Immunization in Rural Ghanaian Infants

H. Sakatoku, MD, T. Nakano, MD, S. Arai, MD and E. A. Afari, MD

Noguchi Memorial Institute for Medical Research (NMIMR), University of Ghana P.O. Box 25, Legon, Ghana

Correspondence: Dr H. Sakatoku, Pediatric Hematology/Oncology Services, Hurley Medical Center, One Hurley Plaza, Flint, Michigan, 48502, USA

We investigated optimal age of measles immunization in infants aged 3–11 months in rural villages of Ghana, and determined seroconversion rate in the same infant population following further attenuated measles vaccination with Schwarz vaccine. The prevalence of passively acquired antibody was 11 per cent in infants younger than 6 months, 10 per cent in infants 6 months old, and 3 per cent in infants 7 months old or older. Seroconversion rates in each age group were less than 50, 87, and 92 per cent, respectively. We then immunized 477-month-old infants. The seroconversion rate was 92 per cent in this group. There were no clinical adverse effects due to the vaccination. We conclude that measles vaccination could be administered effectively at the age of 7 months with an excellent seroconversion rate.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.